News

Sep 25, 2016
The New York Times
Jul 20, 2016
The New England Journal of Medicine Publishes Setmelanotide Phase 2 Data for Treatment of POMC Deficiency Obesity
Peter Kühnen, M.D., Karine Clément, M.D., Ph.D., Susanna Wiegand, M.D., Oliver Blankenstein, M.D., Keith Gottesdiener, M.D., Lea L. Martini, M.D., Knut Mai, M.D., Ulrike Blume-Peytavi, M.D., Annette Grüters, M.D., and Heiko Krude, M.D.
This program is supported by Rhythm, a Boston-based biopharmaceutical company developing the MC4R peptide agonist, setmelanotide (RM-493), for obesity caused by genetic deficiencies in the MC4 pathway.
Back to Top